Palmitoyl Tetrapeptide-7 (Pal-GQPR)

Palmitoyl Tetrapeptide-7 (Pal-GQPR) is Gly-Gln-Pro-Arg acylated at the N-terminus with palmitic acid. The GQPR sequence is linked to a fragment of immunoglobulin G, and the 16-carbon chain boosts lipophilicity, changing how the peptide distributes into membranes, emulsions and other lipid-rich systems. The free tetrapeptide is also known as rigin and shares its C-terminal Pro-Arg with tuftsin (Thr-Lys-Pro-Arg), another short immunoglobulin-derived sequence — worth noting, because it means this peptide is not a true matrikine, since matrikines derive from extracellular-matrix proteins, not antibodies.

It is best known as one of the two peptides in Matrixyl 3000-type formulas, paired with Palmitoyl Tripeptide-1. A separate vial allows labs to study Pal-GQPR by itself, quantify it independently and run single-agent controls before interpreting a two-peptide blend. Published studies lean towards formulation, fibroblast, matrix and cytokine-marker models, and independent evidence is thinner than branded mixture claims might imply. Acylation adds about 238 Da of purely hydrophobic mass, so comparing equal weights with the unmodified sequence means comparing unequal numbers of molecules — designs matched by molarity are the meaningful ones.

The 200 mg vial contains lyophilised Pal-GQPR (CAS 221227-05-0, C34H62N8O7, 694.91 g/mol), HPLC-tested with a certificate of analysis for the lot. It is supplied only as laboratory research material, not as a finished cosmetic or medicinal product.